- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02328612
Randomized, Parallel Group, Placebo Control, Unicentric, Interventional Study to Assess the Effect of Expanded Human Allogeneic Adipose-derived Mesenchymal Adult Stem Cells on the Human Response to Lipopolysaccharyde in Human Volunteers (CELLULA)
Phase I, Randomized, Parallel Group, Placebo Control, Unicentric, Interventional Study to Assess the Effect of Expanded Human Allogeneic Adipose-derived Mesenchymal Adult Stem Cells on the Human Response to Lipopolysaccharyde in Human Volunteers
Phase I, randomized, parallel group, placebo control, unicentric, interventional study. Thirty two healthy male volunteers aged between 18-35 years will be randomized into the eASCs or placebo group if they meet all the inclusion criteria at a 3:1 ratio.
The treatment administration will be infused intravenously to the following groups after randomization:
- First arm: 250,000 cells/kg
- Second arm: 1 million cells/kg
- Third arm: 4 million cells/kg
- Fourth arm: placebo according to their weight.
An hour after the end of the eASCs administration, all subjects will be given an intravenous dose of LPS. Subjects will be allowed to leave in the evening once deemed clinically stable by the investigator.
Study Overview
Detailed Description
Medicinal product Suspension of expanded adipose-derived allogeneic adult stem cells (eASCs) at a single dose of 250,000 cells/kg, 1 million cells/kg or 4 million cells/kg by intravenous infusion after suspension in Ringer's lactate solution.
Control Placebo (Ringer's lactate solution) Objectives To investigate the effect of eASCs on the inflammatory response to intravenous LPS in humans.
Design Phase I, randomized, parallel group, placebo control, unicentric, interventional study. Thirty two healthy male volunteers aged between 18-35 years will be randomized into the eASCs or placebo group if they meet all the inclusion criteria at a 3:1 ratio.
The treatment administration will be infused intravenously to the following groups after randomization:
- First arm: 250,000 cells/kg
- Second arm: 1 million cells/kg
- Third arm: 4 million cells/kg
- Fourth arm: placebo according to their weight.
An hour after the end of the eASCs administration, all subjects will be given an intravenous dose of LPS. Subjects will be allowed to leave in the evening once deemed clinically stable by the investigator.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Amsterdam, Netherlands
- Academic Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
A subject will be eligible for inclusion in this study only if all of the following criteria apply:
- Healthy, as determined by a responsible physician, based on a medical evaluation including medical history, physical examination and laboratory tests carried out within 28 days prior to administration of eASCs (if applicable) and LPS. A subject with a clinical abnormality or laboratory parameter outside the reference range may be included only if the investigator judges that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures
- Male aged between 18 and 35 years, inclusive at the time of signing the informed consent
- Male subjects (including those who have had a vasectomy) must agree to use barrier contraception (latex condoms) when engaging in activity in which conception is possible while on study medication and for at least 28 days after taking the last dose of study medication
- Must understand and voluntarily sign an informed consent form prior to the conduct of any study related assessment/procedures. Capable of giving written informed consent and able to comply with the requirements and restrictions listed in the informed consent form.
Exclusion Criteria:
Subjects meeting any of the following exclusion criteria are not to be enrolled in the study:
- Subject has had a major illness in the past 3 months or any significant chronic medical illness that the investigator would deem unfavourable for enrolment, including inflammatory diseases
- Subjects with a history of malignancy
- Significant concurrent, uncontrolled medical condition including, but not limited to, renal, hepatic, hematological, gastrointestinal, endocrine, pulmonary, neurological, cerebral psychiatric disease, or evidence of demyelinating disease
- Subject uses tobacco products
- Subject has a history, within 3 years, of drug abuse (including benzodiazepines, opioids, amphetamine, cocaine, THC, methamphetamine)
- History of alcoholism and/or drinking more than 5 units of alcohol per day
- Any clinically relevant abnormality noted on the 12-lead ECG as judged by the investigator or an average QTc > 450 msec
- The subject has received an investigational product within three months prior to day 1 of the current study
- Use of prescription or non-prescription drugs and herbal and dietary supplements within 6 months unless in the opinion of the investigator the medication will not interfere with the study procedures or compromise subject safety
- Transfusion of blood or blood products within 6 months prior to the inclusion in the study.
- Subject has difficultly in donating blood or accessibility of a vein in left or right arm.
- Subject has donated more than 350 mL of blood in last 3 months
- Body mass index >28 kg/m2
- Presence of a severe bleeding or thrombotic disorder
- History of known pulmonary embolism or known secondary anti-phospholipid syndrome
- Subjects known or suspected of not being able to comply with a study protocol (e.g. due to alcoholism, drug dependency or psychological disorder)
- Known allergies or hypersensitivity to antibiotics, HSA, DMEM, materials of bovine origin, and Ringer's Lactate Solution
- Any other issue that, in the opinion of the investigator, could be harmful to the subject or compromise interpretation of the data.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: First arm
250,000 cells/kg will be administered via intravenous infusion.
|
The treatment administration will be infused intravenously to the subjects after randomization: An hour after the end of the eASCs administration, all subjects will be given an intravenous dose of LPS. Subjects will be allowed to leave in the evening once deemed clinically stable by the investigator. |
Experimental: Second arm
1,000,000 cells/kg will be administered via intravenous infusion.
|
The treatment administration will be infused intravenously to the subjects after randomization: An hour after the end of the eASCs administration, all subjects will be given an intravenous dose of LPS. Subjects will be allowed to leave in the evening once deemed clinically stable by the investigator. |
Experimental: Third arm
4,000,000 cells/kg will be administered via intravenous infusion.
|
The treatment administration will be infused intravenously to the subjects after randomization: An hour after the end of the eASCs administration, all subjects will be given an intravenous dose of LPS. Subjects will be allowed to leave in the evening once deemed clinically stable by the investigator. |
Placebo Comparator: Fourth arm
Placebo (Ringer's lactate solution) volume according to subject's weight.
|
The treatment administration will be infused intravenously to the subjects after randomization: An hour after the end of the eASCs administration, all subjects will be given an intravenous dose of LPS. Subjects will be allowed to leave in the evening once deemed clinically stable by the investigator. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Inflammatory response as measured by laboratory measurements and functional assays of innate immunology
Time Frame: Change from baseline markers up to 10 hours after LPS injection
|
To investigate the effect of eASCs on the inflammatory response to intravenous LPS in humans.
|
Change from baseline markers up to 10 hours after LPS injection
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- Cx611-0102
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sepsis
-
University of Kansas Medical CenterUniversity of KansasRecruitingSepsis | Septic Shock | Sepsis Syndrome | Sepsis, Severe | Sepsis Bacterial | Sepsis BacteremiaUnited States
-
Jip GroenInBiomeRecruitingMicrobial Colonization | Neonatal Infection | Neonatal Sepsis, Early-Onset | Microbial Disease | Clinical Sepsis | Culture Negative Neonatal Sepsis | Neonatal Sepsis, Late-Onset | Culture Positive Neonatal SepsisNetherlands
-
Karolinska InstitutetÖrebro University, SwedenCompletedSepsis | Sepsis Syndrome | Sepsis, SevereSweden
-
The University of QueenslandRoyal Brisbane and Women's HospitalUnknown
-
Indonesia UniversityCompletedSevere Sepsis With Septic Shock | Severe Sepsis Without Septic ShockIndonesia
-
Ohio State UniversityCompletedSepsis, Severe Sepsis and Septic ShockUnited States
-
Beckman Coulter, Inc.Biomedical Advanced Research and Development AuthorityRecruitingSevere Sepsis | Severe Sepsis Without Septic ShockUnited States
-
University of LeicesterUniversity Hospitals, Leicester; The Royal College of AnaesthetistsCompletedSepsis | Septic Shock | Severe Sepsis | Sepsis SyndromeUnited Kingdom
-
Zagazig UniversityRecruitingSepsis-associated EncephalopathyEgypt
-
Weill Medical College of Cornell UniversityNational Heart, Lung, and Blood Institute (NHLBI); New York Presbyterian Hospital and other collaboratorsCompletedSepsis | Septic Shock | Severe Sepsis | Infection | Sepsis SyndromeUnited States
Clinical Trials on Intravenous infusion of cells
-
Qianfoshan HospitalChinese Medical AssociationRecruiting
-
Celularity IncorporatedCelgene CorporationCompleted
-
Great Ormond Street Hospital for Children NHS Foundation...Completed
-
Shaoxing Second HospitalUnknown
-
Novartis PharmaceuticalsCompletedPigmented Villonodular Synovitis | PVNS | Giant Cell Tumor of the Tendon Sheath | GCCTS | Tenosynovial Giant Cell Tumor Localized or Diffused Type | GCTSUnited States, Switzerland
-
Xiaoyan ZhangCompletedMalignant Solid TumorChina
-
Dana-Farber Cancer InstituteNational Cancer Institute (NCI); Beth Israel Deaconess Medical Center; Brigham...CompletedHematologic MalignancyUnited States
-
Shanghai Public Health Clinical CenterActive, not recruitingRenal Cell Carcinoma | Small Cell Lung Cancer | Hepatocellular Carcinoma | Gastric Cancer | Non-small Cell Lung Cancer | Pancreas CancerChina
-
Andalusian Initiative for Advanced Therapies -...Iniciativa Andaluza en Terapias AvanzadasTerminated
-
Memorial Sloan Kettering Cancer CenterActive, not recruitingMultiple MyelomaUnited States